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hibitors of cyclooxygenase (COX)-2 prevent suppression of aqua-
porin-2 and reduce polyuria in the acute phase after release of bilateral
ureteral obstruction (BUO). We hypothesized that BUO leads to
COX-2-mediated local accumulation of prostanoids in inner medulla
(IM) tissue. To test this, rats were subjected to BUO and treated with
selective COX-1 or COX-2 inhibitors. Tissue was examined at 2, 6,
12, and 24 h after BUO. COX-2 protein abundance increased in IM 12
and 24 h after onset of BUO but did not change in cortex. COX-1 did
not change at any time points in any region. A full profile of all five
primary prostanoids was obtained by mass spectrometric determina-
tion of PGE2, PGF2, 6-keto-PGF1, PGD2, and thromboxane (Tx) B2
concentrations in kidney cortex/outer medulla and IM fractions. IM
concentration of PGE2, 6-keto-PGF1, and PGF2 was increased at 6
h BUO, and PGE2 and PGF2 increased further at 12 h BUO. TxB2
increased after 12 h BUO. 6-keto-PGF1 remained significantly in-
creased after 24 h BUO. The COX-2 inhibitor parecoxib lowered IM
PGE2, TxB2, 6-keto-PGF1, and PGF2 below vehicle-treated BUO
and sham rats at 6, 12 and, 24 h BUO. The COX-1 inhibitor SC-560
lowered PGE2, PGF2, and PGD2 in IM compared with untreated 12
h BUO, but levels remained significantly above sham. In cortex tissue,
PGE2 and 6-keto-PGF1 concentrations were elevated at 6 h only. In
conclusion, COX-2 activity contributes to the transient increase in
prostacyclin metabolite 6-keto-PGF1 and TxB2 concentration in the
kidney IM, and COX-2 is the predominant isoform that is responsible
for accumulation of PGE2 and PGF2 with minor, but significant,
contributions from COX-1. PGD2 synthesis is mediated exclusively
by COX-1. In BUO, therapeutic interventions aimed at the COX-
prostanoid pathway should target primarily COX-2.
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CLINICALLY, URINARY TRACT obstruction accounts for a major
proportion of renal insufficiency (14). Complete urinary tract
obstruction is associated with major changes in glomerular
filtration rate (GFR), renal blood flow (RBF), and tubular
functions. GFR declines immediately after onset of obstruc-
tion, whereas RBF slowly is reduced with progressive increase
in pelvic pressure (4, 17). In parallel, the tubular reabsorption
of sodium and water is altered (15). The decrease in GFR and
RBF is partly mediated by the vasoconstrictors ANG II and
thromboxane A2 (TxA2) (5, 6, 30). Vasodilatory prostaglandins
such as prostaglandin E2 (PGE2) and I2 (PGI2) may be com-
pensatorily released to prevent decrease in GFR and RBF by
antagonizing these vasoconstrictor agents (4). PGE2 and PGI2
are not only vasodilators, but do also have natriuretic and
diuretic properties (23, 24).
Previous studies indicate that cyclooxygenase (COX) activ-
ity contributes to renal function changes immediately after
onset of ureteral obstruction (2, 19, 20). We, and others, have
demonstrated that expression of COX-2 mRNA and protein,
but not COX-1, is markedly increased in the inner medulla
(IM) in response to unilateral ureteral obstruction (UUO) (3)
and bilateral ureteral obstruction (BUO) (2, 19). Administra-
tion of a selective COX-2 inhibitor prevents downregulation of
aquaporin-2 (AQP2) in inner medullary collecting ducts (19)
and attenuates the polyuria observed typically during the first
day after release of 24 h BUO. Urinary excretion of the PGE2
and PGI2 metabolite 6-keto-PGF1 increased significantly after
release of BUO compared with sham operation, and this
increase was abolished by administration of a COX-2 inhibitor,
parecoxib (20). These findings demonstrate that COX-2 ex-
pression is induced after obstruction and that the resulting
PGE2 generation may explain the changes in kidney function.
During experimental ureteral obstruction, it is not possible to
measure prostanoid excretion, and, after release of ureteral
obstruction, the prostanoids detected in urine likely represent a
product arising from glomerular filtration, tubular secretion,
and release from infiltrating inflammatory cells and from the
epithelium lining the urinary tract wall and does not exclu-
sively represent renal medullary COX-2 activity. We hypoth-
esized that the marked increase in renal medullary interstitial
cell COX-2 expression after ureteral obstruction causes a
significant increase in, particularly, PGE2 synthesis and tissue
concentration in the renal medulla. PGE2 is known to inhibit
vasopressin-stimulated osmotic water permeability and sodium
transport in collecting duct principal cells (10, 23).
To address the hypotheses, a kinetic study was designed to
allow for precise determination of temporal correlations be-
tween COX-1 and COX-2 expression and tissue prostanoid
concentration after ureteral obstruction for 2, 6, 12, and 24 h.
A full prostanoid profile [PGE2, PGF2, PGI2 (6-keto-PGF1),
and TxA2 (TxB2)] was determined in extracts of IM and
cortical/outer medulla (C/OM) tissue fractions by gas chroma-
tography/tandem mass spectrometry. To define the contribu-
tion of distinct COX activities to the tissue prostanoid profile
after BUO, the COX-1-selective blocker SC-560 and COX-2-
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selective blocker parecoxib were administrated in separate
experimental series before and during ureteral obstruction and
compared with vehicle-treated BUO rats. Subsequently, kid-
neys were harvested and dissected in C/OM and IM fractions
that were analyzed for prostanoid tissue profile.
METHODS
Experimental Animals
All procedures conformed with the Danish national guidelines for
the care and handling of animals and to the published guidelines from
the National Institutes of Health. The animal protocols were approved
by the board of the Institute of Clinical Medicine, University of
Aarhus, according to the licenses for use of experimental animals
issued by the Danish Ministery of Justice. Studies were performed in
male Munich-Wistar rats initially weighing 220 g (Møllegaard Breed-
ing Centre, Eiby, Denmark). The rats had free access to a standard
rodent diet (Altromin, Lage, Germany) and tap water. During the
experiments, rats were kept in individual metabolic cages, with a
12:12-h light-dark cycle, a temperature of 21  2°C, and a humidity
of 55  2%. Rats were allowed to acclimatize to the cages 3–4 days
before surgery. The rats were placed on anesthesia with isoflurane
(Abbott Scandinavia), and, during the operation, the rats were placed
on a heating pad to maintain rectal temperature at 37–38°C. Through
a midline abdominal incision, both ureters were exposed and then
occluded with a 5–0 silk ligature.
Rats were allocated to the protocols indicated below. Age- and
time-matched, sham-operated controls were prepared and were ob-
served in parallel with each BUO group.
For experiments with a selective COX-2 inhibitor, the protocols
were as follows.
Protocol 1. BUO was induced for 2, 6, 12, and 24 h (n 6 for each
time point). The left kidney was prepared for semiquantitative immu-
noblotting and the right for measurements of prostanoids. In another
group, the left kidney was prepared for immunohistochemistry.
Protocol 2. Sham-operated controls were prepared in parallel (n 
6 for each time point). The left kidney was prepared for semiquanti-
tative immunoblotting and the right for measurements of prostanoids.
In another group, the left kidney was prepared for immunohistochem-
istry.
Protocol 3. BUO was induced for 2, 6, 12, and 24 h, and osmotic
minipumps (Alzet, Scanbur, Denmark) with the selective COX-2
inhibitor parecoxib (Pfizer, Ballerup, Denmark) dissolved in saline
(40 mg/ml) were surgically implanted subcutaneously 24 h before
ureteral obstruction and given at a rate of 5 mg·kg1 ·day1 during
the time of obstruction (n  6 for each time point). Administration of
5 mg·kg1 ·day1 parecoxib was chosen according to the pharmaco-
logical profile of parecoxib as previously demonstrated (21). In this
group, the left kidney was prepared for semiquantitative immunoblot-
ting and the right kidney for measurements of prostanoids.
For experiments with a selective COX-1 inhibitor, the protocols
were as follows.
Rats were deprived of food but had free access to water for 12 h
before administration of vehicle or inhibitors. The compound was
administrated orally, via gavage needle in polyethylene glycol 600
vehicle (10 mg/kg), for a period of 2 h before the obstruction was
performed and during the obstructed period. The doses were selected
based on the published pharmacological profile of SC-560 (27).
Protocol 4. BUO was induced for 12 and 24 h (n  6 for each time
point), and rats were treated with vehicle. The right kidney was
prepared for measurements of prostanoids.
Protocol 5. Sham-operated controls were prepared in parallel and
treated with vehicle (n  6 for each time point). The right kidney was
prepared for measurements of prostanoids.
Protocol 6. BUO was induced for 12 and 24 h, and rats were treated
with the selective COX-1 inhibitor SC-560 (Cayman Chemicals, Ann
Arbor, MI) (n 7 for each time point). The right kidney was prepared
for measurements of prostanoids.
Measurement of Prostanoid Concentration in Kidney Tissue
The tissue was homogenized in ice-cold PBS buffer containing 10
mol/l indomethacin. Protein concentration was measured using the
Pierce BCA protein assay kit. In an isotope dilution assay, PGE2, the
PGI2 metabolite 6-keto-PGF1, PGF2, PGD2 and TxB2 were deter-
mined in IM and C/OM using gas chromatography/tandem mass
spectrometry (GC-MS-MS). After addition of deuterated internal
standards, the prostanoids were derivatized to methoximes and ex-
tracted with ethyl acetate-hexane. The samples were further derivat-
ized to the pentafluorobenzyl esters and purified using thin-layer
chromatography (TLC). Three zones were scraped from the TLC. The
prostanoid derivatives were converted to the trimethylsilyl ethers and
the products quantified using GC-MS-MS.
GC-MS-MS Analysis
A Finnigan MAT TSQ700 GC-MS-MS equipped with a Varian
3400 gas chromatograph and a CTC A200S autosampler was used.
Gas chromatography of prostanoid derivatives was carried out on a (J
& W) DB-1 (20 m, 0.25 mm ID, 0.25-m film thickness) capillary
column (Analyt, Mühlheim, Germany) in the splitless mode. GC-
MS-MS parameters were exactly as described by Schweer et al. (26).
Tissue Handling for Immunoblotting
The tissue (C/OM and IM) was homogenized in dissecting buffer
[0.3 M sucrose, 25 mM imidazole, 1 mM EDTA, pH 7.2, containing
the following protease inhibitors: 8.5 M leupeptin (serine and
cysteine protease inhibitor; Sigma-Aldrich) and 0.4 mM pefabloc
(serineprotease inhibitor; Roche)]. Moreover, the dissecting buffer for
IM was added following phosphatase inhibitors sodium ortho-Vana-
dat (Sigma-Aldrich), Na-F (Merck), and okadic acid (Calbiocham).
The tissue was homogenized for 30 s at 1,250 rpm by an Ultra-Turrax
T8 homogenizer (IKA Labortechnik) and then centrifuged at 1,500 g
at 4°C for 15 min. Gel samples were prepared from the supernatant in
Laemmli sample buffer containing 2% SDS. The total protein con-
centration of the homogenate was measured using a Pierce BCA
protein assay kit (Roche).
Electrophoresis and Immunoblotting
Homogenized samples from C/OM and IM were run on 12%
polyacrylamide minigels (Bio-Rad Mini Protean II). For each gel, an
identical gel was run in parallel and subjected to Coomassie staining.
The Coomassie-stained gel was applied to determine identical loading
or to allow for correction for minor variations in loading.
Samples were run on 9, 10, and 12% polyacrylamide gels (Protean
II; Bio-Rad). Proteins were transferred to a nitrocellulose membrane
(Hybond ECL RPN 3032D; Amersham Pharmacia Biotech). After-
ward, the blots were blocked with 5% nonfat dry milk in PBS-T (80
mM Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1% Tween 20,
adjusted to pH 7.4). After being washed in PBS-T, the blots were
incubated with primary antibodies overnight at 4°C. Antigen-antibody
complex was visualized with horseradish peroxidase-conjugated sec-
ondary antibodies (P448, diluted 1:3,000; DAKO, Glostrup, Den-
mark) using the enhanced chemiluminiscence system (ECL; Amer-
sham Pharmacia Biotech). Immunolabeling controls were performed
using peptide-absorbed antibody.
Primary Antibodies
For semiquantitative immunoblotting and immunohistochemistry,
we used previously characterized monoclonal and polyclonal antibod-
ies summarized as follows: COX-1 (catalog no. 160109; Cayman
Chemical, Ann Arbor, MI), an affinity-purified rabbit polyclonal
antibody against COX-1; COX-2 (catalog no. 160126; Cayman
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Chemical), an affinity-purified rabbit polyclonal antibody against
COX-2; PGE2 synthase (PGES; catalog no. 160140; Cayman Chem-
ical), an affinity-purified rabbit polyclonal antibody against PGES;
AQP2 (H7661), an affinity-purified antibody to AQP2, as previously
described (18).
Immunohistochemistry
The kidneys from BUO rats and sham-operated control rats were
fixed by retrograde perfusion via the abdominal aorta with 3%
paraformaldehyde in 0.1 M cacodylate buffer, pH 7.4. Moreover, the
kidneys were immersion fixed for 1 h and washed 3 10 min with 0.1
M cacodylate buffer. The kidney blocks were dehydrated and embed-
ded in paraffin. The paraffin-embedded tissues were cut in 2-m
sections on a rotary microtome (Leica Microsystems, Herlev, Den-
mark).
For immunoperoxidase labeling, the sections were deparaffinized
and rehydrated. Endogenous peroxidase activity was blocked with 5%
H2O2 in absolute methanol for 10 min at room temperature. To expose
antigens, kidney sections were boiled in a target retrieval solution (1
mmol/l Tris, pH 9.0, with 0.5 mM EGTA) for 10 min. After cooling,
nonspecific binding was prevented by incubating the sections in 50
mM NH4Cl in PBS for 30 min, followed by blocking in PBS
containing 1% BSA, 0.05% saponin, and 0.2% gelatine. Sections were
incubated with primary antibodies diluted in PBS with 0.1% BSA and
0.3% Triton X-100 overnight at 4°C. After being washed 3  10 min
with PBS supplemented with 0.1% BSA, 0.05% saponin, and 0.2%
gelatine, the sections were incubated with horseradish peroxidase-
conjugated secondary antibody (P448, goat anti-rabbit immunoglob-
ulin; DAKO) for 1 h at room temperature. After being rinsed with
PBS wash buffer, the sites of antibody-antigen reactions were visu-
alized with 0.05% 3,3=-diaminobenzidine tetrachloride (Kem-en Tek,
Copenhagen, Denmark) dissolved in distilled water with 0.1% H2O2.
The light microscope was carried out with Lecia DMRE (Leica
Microsystem, Herlev, Denmark).
Statistics
Values are presented as means  SE. Statistical comparisons
between experimental groups were made by a standard unpaired t-test.
P values 0.05 were considered significant.
RESULTS
Time Course of Changes in Total Prostanoid Tissue
Concentration in Renal IM and C/OM in Response to BUO
To evaluate the relative importance of each COX isoform for
intrarenal prostanoid synthesis in response to ureteral obstruc-
tion, rats were subjected either to sham operation or BUO for
2, 6, 12, and 24 h. BUO rats were subcutaneously given either
vehicle or a selective COX-2 inhibitor, parecoxib (5 mg·kg1·
day1), through osmotic minipumps, and tissue prostanoid concen-
tration was determined in IM and C/OM tissue fractions by
GC-MS-MS (Fig. 1). Tissue concentration was significantly
higher in the IM compared with the C/OM fraction for each
measured prostanoid at all time points (10–150 times; Fig.
1). In IM tissue, the ratios between concentration of prostanoid
groups in sham rats were PGE2 	 TxB2 	 PGF2 	 6-keto-
PGF1 	 PGD2, whereas in C/OM there were no significant
differences in concentration (Fig. 1). The prostacyclin metab-
olite 6-keto-PGF1 and PGF2 tissue concentrations displayed
the earliest detectable change at the tissue level. Tissue con-
centrations of PGE2, the PGI2 metabolite 6-keto-PGF1, and
PGF2 increased significantly at 6 h after BUO in IM compared
with sham (Table 1). After 12 h, the IM concentrations of
PGE2, PGF2, and TxB2 were all significantly elevated in BUO
rats compared with sham (Table 1). At 24 h BUO, 6-keto-
PGF1 IM concentration remained significantly elevated,
whereas PGF2, PGE2, and TxB2 returned to levels not signif-
icantly different from levels in sham-operated control rats
(Table 1). PGD2 tissue concentration was not altered in IM by
BUO compared with sham (Table 1).
In the kidney C/OM tissue fraction, PGE2 and 6-keto-PGF1
concentrations increased significantly at 6 h post-BUO compared
with sham-operated rats. Furthermore, TxB2 concentration in
C/OM was increased in response to 24 h BUO (Table 2).
Effect of a Selective COX-2 Inhibitor on Kidney Tissue
Prostanoid Concentration in Response to BUO
COX-2 inhibition with parecoxib (5 mg·kg1 ·day1) sup-
pressed PGE2 tissue concentration compared with BUO vehi-
cle at 6, 12, and 24 h in IM. After BUO for 6, 12, and 24 h,
parecoxib treatment suppressed PGE2 levels significantly be-
low that observed in sham-operated and vehicle-treated BUO
rats (Table 1). Parecoxib attenuated both prostacyclin metab-
olite 6-keto-PGF1 and PGF2 concentration in IM compared
with BUO and sham operation at all time points (2, 6, 12, and
24 h; Table 1). Moreover, parecoxib lowered the IM tissue
concentration of the TxA2 metabolite TxB2 significantly at 6,
12, and 24 h compared with vehicle-infused BUO rats and
sham-operated rats (Table 1). In marked contrast, IM tissue
concentration of PGD2 was significantly elevated after 2 and 6
h in BUO rats treated with parecoxib compared with vehicle-
treated BUO rats, whereas, at 12 h BUO, the PGD2 concen-
tration was lower than in BUO vehicle rats. At 24 h, there were
no differences in PGD2 concentrations (Table 1).
In C/OM, administration of parecoxib did not significantly
change the BUO-induced increase in PGE2 and 6-keto-PGF1
at 6 h BUO. However, at 24 h BUO, 6-keto-PGF1 tissue
concentration was significantly suppressed by administration
of parecoxib compared with vehicle-treated BUO rats (Table
2). Parecoxib administration suppressed the concentration of
TxB2 at 12 and 24 h BUO compared with BUO vehicle and
sham-operated rats (Table 2). PGF2 in C/OM tissue was
lowered significantly by parecoxib compared with BUO and
sham rats after 24 h (Table 2). Similar to IM, PGD2 concen-
tration in C/OM tissue responded differently compared with
Fig. 1. Basal prostanoid profiles in renal inner medulla (IM) and cortex
 outer
medulla (C 
 OM). Bars in each group from left to right represent PGE2,
PGF2, 6-keto-PGF1, thromboxane (Tx) B2, and PGD2; n  6 rats in each
group.
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the other prostanoids; tissue concentration was elevated signif-
icantly by parecoxib at 6, 12, and 24 h compared with BUO
vehicle and sham-operated rats (Table 2).
Effect of a Selective COX-1 Inhibitor on Kidney Tissue
Prostanoid Concentration in Response to BUO
To investigate the contribution of COX-1 activity to the
BUO-induced changes in prostanoid production in the IM, a
separate series of rats were subjected to 12 and 24 h BUO and
treated with the selective COX-1 inhibitor SC-560 (10 mg/kg)
or vehicle. The absolute level of tissue prostanoid concentra-
tions was lower in this series, but the relative changes in
response to BUO were similar to the previous series. Thus, all
five measured prostanoids exhibited an elevated tissue concen-
tration after 12 h BUO, and, after 24 h, PGE2 and 6-keto-
PGF1 remained significantly elevated. Administration of SC-
560 resulted in a significant lower tissue concentration of
PGE2, PGF2, and PGD2 at 12 h compared with vehicle-treated
BUO rats. Although significantly suppressed compared with BUO
vehicle rats at 12 h, PGE2 and PGF2 tissue concentrations were
still significantly elevated above sham, whereas PGD2 was essen-
tially normalized by COX-1 inhibition (Table 3).
Time Course of Changes in COX Protein Abundance and
Localization in Response to BUO
The abundance of COX-1 protein did not change in response
to BUO in IM and C/OM during the time course of the
experiment (Fig. 2, A and B). COX-2 protein abundance
increased significantly in IM tissue after 12 and 24 h of BUO
(Fig. 3A). COX-2 protein abundance did not change signifi-
cantly in the C/OM tissue fraction during the experiment (Fig.
3B). Immunohistochemical staining of kidney IM sections for
COX-2 confirmed essentially the Western blotting results: at the
base of IM in rats subjected to 12 and 24 h of BUO (Fig. 4, F and H),
Table 1. Profile of prostanoid production in inner medulla in nontreated and parecoxib-treated BUO rats for 2, 6, 12, and
24 h and sham-operated control rats
Time, h PGE2 6-Keto-PGF1 PGF2 TxB2 PGD2
2
Sham 140 12.5 24  1.6 31 3.0 40  4.7 15  2.0
BUO 144 26.7 27  2.1 27 5.1 26  5.6 10  1.9
BUO 
 pc 102  3.8 13  1.9†‡ 15 0.5†‡ 31  3.2 27  1.6†‡
6
Sham 136 11.0 20  1.0 33 3.0 52  6.8 18  2.5
BUO 188 14.4* 29  2.8* 53 4.3* 62  4.9 19  2.1
BUO 
 pc 93  9.8†‡ 10  1.2†‡ 21 1.2†‡ 27  2.0†‡ 34  9.8†‡
12
Sham 125 4.8 35  8.9 50 13.3 82  24.6 39  12.8
BUO 319 57.2* 48  4.2 102 11.1* 164  17.2* 62  9.2
BUO 
 pc 64  6.8†‡ 17  2.5†‡ 20 2.4†‡ 38  3.0†‡ 26  4.3†
24
Sham 215 22.4 52  4.7 48 2.8 89  9.9 22  4.3
BUO 174 24.3 76  10.7* 54 9.0 108  16.8 19  2.3
BUO 
 pc 46  2.4†‡ 12  1.5†‡ 14 1.0†‡ 32  4.0†‡ 14  1.2
Values are means  SE for n  6 rats in each group. Units are pg/g tissue. TxB2, thromboxane B2; BUO, bilateral ureteral obstruction; pc, parecoxib.
P  0.05, respective prostanoids in nontreated BUO vs. sham-operated control rats (*), respective prostanoids in nontreated BUO vs. parecoxib-treated BUO
rats (†), and respective prostanoids in parecoxib-treated BUO vs. sham-operated control rats (‡).
Table 2. Profile of prostanoid production in cortex/outer medulla in nontreated and parecoxib-treated BUO rats for 2, 6, 12,
and 24 h and sham-operated control rats
Time, h PGE2 6-Keto-PGF1 PGF2 TxB2 PGD2
2
Sham 1.5 0.17 2.0  0.42 1.9  0.32 4.3 0.24 0.62 0.10
BUO 1.5 0.24 1.8  0.35 2.0  0.29 4.9 0.80 0.51 0.08
BUO 
 pc 1.1  0.21 1.3  0.16 1.8  0.50 3.8 0.46 0.83 0.25
6
Sham 0.8 0.03 1.1  0.13 1.0  0.07 2.8 0.04 0.32 0.03
BUO 1.7 0.18* 2.5 0.20* 1.4  0.10 2.9 0.15 0.33 0.03
BUO 
 pc 1.3  0.07 1.6  0.20 1.5  0.25 2.7 0.45 0.97 0.12†‡
12
Sham 1.2 0.11 1.5  0.28 1.0  0.20 3.0 0.33 0.28 0.04
BUO 1.5 0.16 1.7  0.16 1.4  0.20 3.4 0.56 0.41 0.11
BUO 
 pc 1.8  0.24 1.0  0.09 1.0  0.09 1.8 0.08†‡ 0.76 0.06†‡
24
Sham 1.0 0.10 1.8  0.28 2.4  0.26 4.6 0.68 0.52 0.10
BUO 1.8 0.40 3.2  0.76 1.9  0.35 7.3 1.08* 0.50 0.10
BUO 
 pc 1.5  0.14 1.4  0.17† 1.0  0.10†‡ 2.1 0.38†‡ 0.83 0.06†‡
Values are means  SE for n  6 rats in each group. Units are pg/g tissue. P  0.05, respective prostanoids in nontreated BUO vs. sham-operated control
rats (*), respective prostanoids in nontreated BUO vs. parecoxib-treated BUO rats (†), and respective prostanoids in parecoxib-treated BUO vs. sham-operated
control rats (‡).
R1020 RENAL PROSTANOIDS GENERATION DURING URETERAL OBSTRUCTION
AJP-Regul Integr Comp Physiol • VOL 298 • APRIL 2010 • www.ajpregu.org
 by 10.220.33.1 on January 15, 2017
http://ajpregu.physiology.org/
D
ow
nloaded from
 
the COX-2 labeling was more widespread, intense, and exclu-
sively associated with the medullary interstitial cells compared
with kidneys from sham-operated rats. In sham rats, COX-2
labeling in the kidney medulla was at the limit of detection
(Fig. 4, E and G). There was no visible difference between rats
subjected to 2 or 6 h of BUO and sham-operated controls (Fig.
4, A–D).
To investigate the time course of the changes in microsomal
PGES, semiquantitative immunoblotting experiments were
Table 3. Profile of prostanoid production in inner medulla of vehicle-treated rats and rats treated with a cyclooxygenase-1
inhibitor (SC-560) in BUO rats for 12 and 24 h and sham-operated control rats
Time, h PGE2 6-Keto-PGF1 PGF2 TxB2 PGD2
12
Sham 1.4  0.4 1.2 0.3 1.3  0.2 0.20 0.03 0.11 0.01
BUO 10.1  1.8* 7.0 4.2* 4.3  0.7* 0.35 0.01* 0.30 0.02*
BUO 
 SC-560 5.1 1.0†‡ 5.4 0.7‡ 2.7  0.4†‡ 0.29 0.03 0.20 0.02†
24
Sham 0.95  0.2 2.0 0.2 2.0  2.8 0.74 0.12 0.25 0.04
BUO 5.0  1.2* 4.4 0.7* 4.8  1.3 0.55 0.08 0.43 0.16
BUO 
 SC-560 4.5 0.6‡ 3.2 0.4‡ 4.8  1.6 0.59 0.09 0.21 0.03
Values are means SE for n 6 rats in each group. Units are pg/g tissue. P 0.05, respective prostanoids in nontreated BUO vs. sham-operated control rats (*),
respective prostanoids in nontreated BUO vs. SC-560-treated BUO rats (†), and respective prostanoids in SC-560-treated BUO vs. sham-operated control rats (‡).
Fig. 2. Semiquantitative immunoblots of cyclooxygenase (COX)-1 using
kidney protein isolated from IM and C/OM from bilateral ureteral obstructed
(BUO) rats for 2, 6, 12, and 24 h and sham-operated control rats. A total of 20
g protein was used for the COX-1 assay. A: densitometric analysis of all the
samples from IM from obstructed kidneys and sham rats revealed that there
was no difference between the different time points in the obstructed rats and
control. B: densitometric analysis of all the samples from C/OM from ob-
structed kidneys and sham rats revealed that there was no difference between
the different time points in the obstructed rats and control.
Fig. 3. Semiquantitative immunoblots of COX-2 using kidney protein isolated
from IM and C/OM from BUO rats for 2, 6, 12, and 24 h and sham-operated
control rats. A total of 30 g protein was used for the COX-2 assay.
A: densitometric analysis of all the samples from IM from obstructed kidneys and
sham rats revealed that COX-2 protein abundance was increased when rats were
subjected to 12 and 24 h BUO compared with control. *P  0.05 vs. control rats
in each group. B: densitometric analysis of all the samples from C/OM from
obstructed kidneys and sham rats revealed that there was no difference between the
different time points in the obstructed rats and control.
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performed with IM and C/OM. The abundance of PGES protein
was unchanged in IM (Fig. 5). There was a tendency toward
decreased PGES abundance after 24 h BUO, but this was not
significant (Fig. 5A). In C/OM, the abundance of PGES
protein did not change during the time course of the exper-
iments (Fig. 5B).
Effect of the Selective COX-2 Inhibitor on AQP2 Protein
Expression in Response to BUO
The time course of the effect of the COX-2 inhibitor pare-
coxib on AQP2 protein abundance in IM was determined.
Semiquantitative immunoblotting for AQP2 was performed
with IM protein samples from rats subjected to 2, 6, 12, or 24
h of BUO. The abundance of AQP2 protein in IM was
significantly decreased at 12 and 24 h of BUO (Fig. 6). The
BUO-induced downregulation of AQP2 was attenuated signif-
icantly by administration of the selective COX-2 inhibitor
parecoxib at 12 and 24 h (Fig. 6).
DISCUSSION
The main results of the present study were that BUO led
to increased tissue concentration of prostanoids (PGE2,
PGF2, TxB2) predominantly in the renal IM that peaked at
12 h after the occlusion and then largely normalized at 24 h.
The prostacyclin metabolite 6-keto-PGF1 peaked after 24 h
BUO.
The sum of data support that the acute antidiuretic and
natriuretic action of COX-2 inhibitors after release of ureteral
obstruction (20) is caused by an action in the renal medulla.
Thus, there was a close temporal and spatial correlation be-
tween a rise in COX-2 expression in interstitial cells and an
increased tissue concentration of prostanoids with arginine
vassopressin (AVP)-antagonizing capability in IM, but not in
cortex; the IM tissue concentration of PGE2, PGI2, PGF2, and
TxA2 all displayed marked sensitivity to a COX-2 inhibitor,
and concentrations were essentially normalized or further low-
ered during BUO, whereas a COX-1 inhibitor had limited
Fig. 4. Immunohistochemistry for COX-2 in kidney IM of
sham-operated (A, C, E, and G) and BUO rats for 2 (B), 6
(D), 12 (F), and 24 (H) h. Only interstitial cells (indicated
by arrows) of IM are labeled. There is a strong labeling at
the base of IM from obstructed kidneys from 12 (F) and 24
(H) h, and labeling is not detectable in sham kidneys (A, C,
E, and G) and obstructed kidneys from 2 (B) and 6 (D) h.
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effect on PGE2 and PGF2 concentrations only, and concen-
trations were not normalized.
The total prostanoid content was one to two orders of
magnitude higher in IM than C/OM in rats. This is consistent
with previous studies showing an increased total amount of
prostanoids in IM compared with cortex in normal rats (11).
Moreover, it is in keeping with the expected gradient of the
obstruction-mediated impact on kidney tissue where IM is
likely to be exposed most rapidly and strongly to increased
retrograde pressure gradient and its consequences. The data
suggest that COX-2 activity in the inner medullary interstitial
cells can provide substrate for an array of downstream prosta-
noid synthases which indicates either preexisting colocaliza-
tion or induction of synthases in medullary cells in response to
BUO. Indeed, PGES was detected in the IM and has been
shown in inner medullary interstitial cells and collecting ducts
(25). The PGES can be induced by cytokines and inflammatory
stimuli (13), and it is believed that PGES is functionally
coupled to COX-2 in the medullary interstitial cells and con-
tributes to PGE2 biosynthesis in these cells. However, in the
collecting ducts, the inducible PGES is coupled to COX-1 (25).
Our data support that the collecting duct COX-1-PGES pair
contributes to the BUO-induced tissue PGE2 accumulation.
Our data showed that PGES protein expression is not signifi-
cantly changed in response to obstruction in IM and therefore
likely is not a limiting factor. Little data are available with
regard to localization of the other prostanoid synthases in
kidney tissue. However, studies have shown that prostacyclin
synthase mRNA is mainly localized in the vasculature and throm-
boxane synthase mRNA is detected mainly in glomeruli (28).
In accordance with our observations, it has been demon-
strated that BUO for 24 h enhances PGI2 production in med-
ullary isolated tubules of the rat kidney (29). In contrast with
our observations, Yanagisawa et al. (29) also showed increased
PGE2 and TxB2 levels in medullary isolated tubules in re-
sponse to 24 h BUO. The literature demonstrates conflicting
results regarding the time course of changes of prostanoid
tissue concentration in kidney medulla after obstruction. Thus,
it was previously demonstrated that PGE2 and TxB2 production
in papilla and isolated medullary tubules was reduced after 24
h BUO (7). In agreement, the present study showed that PGE2
and TxB2 levels returned to control level in IM after 24 h BUO,
which indicates that BUO-induced changes in kidney tissue
prostanoid concentration are transient, which may reconcile
these inconsistent observations. We have not examined the
mechanism involved in the transient production of PGE2,
TxB2, and PGF2 in IM after 24 h BUO.
At one side, prostanoid tissue concentrations were increased
at 6 h BUO before measureable changes in COX-2 protein
abundance, and, at the other side, COX-2 protein was increased
after 24 h BUO, when most prostanoids had returned to control
levels. Thus, early activation of phospholipase and liberation of
Fig. 6. Semiquantitative immunoblots of aquaporin-2 (AQP2) using kidney
protein isolated from IM from nontreated and parecoxib (pc)-treated BUO rats
for 2, 6, 12, and 24 h and sham-operated control rats. A total of 10 g protein
was used for the AQP2 assay. Densitometric analysis revealed that AQP2
expression in IM was markedly decreased in rats subjected to BUO for 12 and
24 h compared with sham-operated control rats. Parecoxib treatment of BUO
rats prevented this decrease in AQP2 expression. P  0.05 compared with
sham-operated rats (*) and with parecoxib-treated BUO rats (#).
Fig. 5. Semiquantitative immunoblots of PGE2 synthase (PGES) using kidney
protein isolated from IM and C/OM from BUO rats for 2, 6, 12, and 24 h and
sham-operated control rats. A total of 30 g protein was used for the PGES
assay. A: densitometric analysis of all the samples from IM from obstructed
kidneys and sham rats revealed that there was no difference between the
different time points in the obstructed rats and control. B: densitometric
analysis of all the samples from C/OM from obstructed kidneys and sham rats
revealed that there was no difference between the different time points in the
obstructed rats and control.
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arachidonic acid with subsequent metabolization by COX-2,
which is present in interstitial cells also in the control situation
(1), is probably causing the early increase in tissue prostanoid
concentration. This interpretation is supported by the signifi-
cant effect of the COX-2 inhibitor to lower, e.g., tissue, PGE2
concentration at 6 h BUO. Beyond 24 h BUO, substrate
depletion, lower phospholipase activity, or downstream syn-
thase downregulation could explain normal prostanoid levels
despite elevated COX-2 protein levels. Furthermore, prosta-
noids may exert feedback inhibition (12), and Lemieux et al.
(16) demonstrated in renal podocytes that PGE2 reduces ara-
chidonic acid release in a cAMP/PKA-dependent manner.
In agreement with previous observations in BUO and UUO
models, COX-1 expression did not change in response to
obstruction in IM (3, 19), but COX-1 activity contributed to
BUO-induced accumulation of PGE2, PGF2, and PGD2 at 12
h, but prostanoid levels were still significantly elevated, which
documents clearly that COX-2 activity is necessary to account
for the tissue response to BUO.
The difference in absolute tissue prostanoid concentrations
in the COX-1 inhibitor series could have been caused by a
longer tissue storage before processing.
Previous studies have indicated that COX-1 predominately
contributes to basal prostanoid production in the kidney (11,
22). Although we did not determine the effect of COX blockers
in sham-operated animals, our results suggest that both en-
zymes contribute to tissue levels of renal PGE2 and PGF2 and
that COX-2 preferentially couples to PGI2 synthesis while,
interestingly, renal PGD2 synthesis appears to be exclusively
mediated by COX-1. PGD2 tissue concentration increased
significantly after COX-2 inhibition. This observation could be
explained by competition between COX-1 and COX-2 for
arachidonic acid in PGD synthase-expressing cells and would
be compatible with the observed effect of the COX-1 inhibitor
to suppress PGD2 tissue level.
Ureteral obstruction causes a temporary increase in blood
flow during the first 2–5 h in the obstructed kidney, predomi-
nantly caused by preglomerular vasodilation, followed by pro-
gressive preglomerular vasoconstriction (14). Local production
of the vasodilator PGE2 and PGI2 was noted after 6 h in C/OM
(and IM) and may account for the increased RBF. In accord
with data that show a progressive decrease in RBF mediated by
ANG II, TxB2, and endothelin (14), we found an increased
production of TxB2 in C/OM. The increased TxB2 in IM could
contract descending vasa recta and consequently add to the
RBF decrease. Imidazole, an inhibitor of thromboxane synthe-
sis, increases medullary blood flow in conscious rats (8).
Ureteral obstruction affects tubular function (15). There is a
marked diuresis and natriuresis after release of BUO of 24 h
duration (9, 20). PGE2 and PGI2 not only are vasodilators but
also have direct natriuretic and diuretic properties (24). Ad-
ministration of a selective COX-2 inhibitor to rats subjected to
24 h BUO followed by release of obstruction prevents the
increased urinary excretion of PGE2 and PGI2 metabolite
6-keto-PGF1; it also lowers diuresis and prevents downregu-
lation of collecting duct AQP2 (20). The present study con-
firms these observations on AQP2 and supports that enhanced
COX-2 expression and activity in the obstructed kidney after
12 and 24 h BUO is involved in the downregulation of AQP2.
Perspectives and Significance
The present study examines the relationship between COX-
2/COX-1 expression and tissue prostanoid concentration after
acute ureteral obstruction for 2, 6, 12, and 24 h by defining the
renal prostanoid profiles in renal tissue using a specific COX-1
and COX-2 inhibitor. Our data indicate that BUO leads to rapid
and significant increases in local tissue prostanoid concentra-
tion in the renal IM mediated preferentially by increased
COX-2 abundance and activity. These findings suggest that
local synthesis and accumulation of prostanoids in the renal IM
could play a role in the dysregulation of renal tubular function
and medullary hemodynamics observed in response to BUO.
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